Full history for every metric is available with a Kvantra account
HilleVax, Inc. (HLVX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -155 | -77 | |||||
| Net profit | $m | -1 | -2 | -85 | -257 | -124 | -147 | -71 |
| EPS reported | $ | -3.00 | -1.43 | |||||
| Operating cashflow per share | $ | -2.21 | -0.27 | |||||
| Capex per share | $ | 0.01 | 0.00 | |||||
| FCF per share | $ | -2.22 | -0.27 | |||||
| Free cash flow | $m | -109 | -61 | |||||
| Net debt | $m | -171 | -160 | |||||
| Book value equity | $m | 154 | 148 | |||||
| Book value per share | $ | 3.14 | 2.95 | |||||
| Number of shares | m | 49.15 | 50.11 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.66 | 0.71 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.93 | -1.71 | |||||
| EV/EBITDA LTM | x | 0.18 | 0.82 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -144.74% | -10.81% | |||||
| FCF Yield | % | -107.44% | -58.55% | |||||
| Quality | ||||||||
| ROE | % | -95.33% | -7.58% | |||||
| ROIC | % | -86.37% | -8.46% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -100.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -4.46 | -2.61 | |||||
| Net Debt/EBITDA | x | 0.84 | 3.39 | |||||
| EBIT/Net interest | x | 46.80 | 0.00 | |||||
| Net debt/market cap | % | -168.49% | -152.29% | |||||
| Net debt/Equity | x | -1.11 | -1.08 | |||||
| Gross debt/equity | x | 0.16 | 0.16 | |||||
Company overview
HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
HilleVax, Inc. (HLVX)
HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free